Table 1 Presenting features of the 97 patients with ET or PMF, stratified according to their mutational status
JAK2 mutated (A) | CALR mutated (B) | Triple negative | p (A vs B)* | |
|---|---|---|---|---|
ET (N = 88) | ||||
No. of patients, n (%) | 57 (65) | 19 (21) | 12 (14) | |
Age, median (range), year | 66 (33–86) | 58 (30–85) | 66.5 (29–82) | 0.056 |
Age ≧ 60 year, n (%) | 42 (74) | 8 (42) | 8 (67) | 0.012 |
Females, n (%) | 33 (58) | 9 (47) | 5 (42) | 0.439 |
Leukocytes, median (range), ×109/L | 12.1 (6.0–42.3) | 9.2 (5.3–16.3) | 8.4 (4.6–13.9) | <.001 |
Hemoglobin, median (range), g/dL | 14.3 (10.2–18.6) | 13.5 (11.4–17.1) | 13.7 (11.3–16.2) | 0.593 |
Platelets, median (range), ×109/L | 867 (489–2285) | 930 (631–2336) | 717 (501–922) | 0.359 |
NAP score median (range) | 312 (202–417) | 215 (106–286) | 254.5 (116–404) | <.001 |
High LD, n (%) | 38 (67) | 11 (58) | 3 (25) | 0.489 |
Palpable splenomegaly, n (%) | 19 (33) | 3 (16) | 1 (8) | 0.144 |
Thrombosis history, n (%) | 22 (39) | 2 (11) | 3 (25) | 0.023 |
Needed to cytoreductive therapy, n (%) | 39 (68) | 12 (63) | 5 (42) | 0.672 |
PMF (N = 9) | ||||
No. of patients, n (%) | 5 (56) | 2 (22) | 2 (22) | |
Age, median (range), year | 65 (51–85) | 63.5 (58–69) | 67.5 (57–78) | NA |
Age ≧ 60 year, n (%) | 4 (80) | 1 (50) | 1 (50) | NA |
Females, n (%) | 3 (60) | 1 (50) | 1 (50) | NA |
Leukocytes, median (range), ×109/L | 14.4 (8.6–37.1) | 5.8 (5.6–6.1) | 5.1 (5.0–5.3) | NA |
Hemoglobin, median (range), g/dL | 13.2 (9.8–16.8) | 12.2 (11.7–12.6) | 11.1 (8.9–13.3) | NA |
Platelets, median (range), ×109/L | 384 (194–654) | 306 (260–352) | 383 (122–644) | NA |
NAP score median (range) | 341 (301–378) | 157 (150–164) | 253.5 (210–297) | NA |
High LD, n (%) | 5 (100) | 2 (100) | 1 (50) | NA |
Palpable splenomegaly, n (%) | 5 (100) | 2 (100) | 0 (0) | NA |
Thrombosis history, n (%) | 1 (20) | 0 (0) | 1 (50) | NA |
Needed to cytoreductive therapy, n (%) | 1 (20) | 0 (0) | 1 (50) | NA |